-

GE HealthCare announces cash dividend for second quarter of 2025

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2025 payable on August 15, 2025 to all shareholders of record as of July 25, 2025.

About GE HealthCare Technologies Inc.

GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.R.fox@gehealthcare.com

Industry:

GE HealthCare Technologies Inc.

NASDAQ:GEHC
Release Versions
English

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.R.fox@gehealthcare.com

More News From GE HealthCare Technologies Inc.

GE HealthCare aims to advance a new era in theranostics with StarGuide™ GX 4D SPECT/CT, now 510(k) pending with the U.S. FDA

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that StarGuide GX,i its new digital 4D CZT SPECT/CT technology, is 510(k) pending with the U.S. Food and Drug Administration (FDA). Building on the system’s recent CE Mark, this milestone is a step towards expanding access to advanced molecular imaging technologies in the United States and marks a significant moment in molecular imaging’s evolution – aiming to empower clinicians with a high-performance, general purpose scanner to help pers...

GE HealthCare’s Photonova™ Spectra gains CE Mark, expanding international access

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) recently achieved CE Mark for Photonova Spectra,i an advanced photon-counting computed tomography (PCCT) system with the company’s proprietary Deep Silicon™ detector technology. The regulatory milestone expands access and enables clinical adoption of the technology in CE Mark–observing countries and underscores GE HealthCare’s commitment to purposeful, customer-driven innovation in computed tomography (CT). “We are proud to deliver this new...

GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus....
Back to Newsroom